A look, in numbers, at the forces shaping electronic medicine.
Antonio RegaladoFollow @twitterapi
Senior Editor, Business
I am the business editor of MIT Technology Review. I look for stories about how technology is changing business. Before joining MIT Technology Review in July 2011, I lived in São Paulo, Brazil, where I wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2009, I was the science reporter at the Wall Street Journal and later a foreign correspondent.
Antonio Regalado's Stories
A small biotech firm is the second company to start human tests of embryonic stem-cell therapy.
After years of controversy, a therapy based on human embryonic stem cells is finally being tested in humans. The treatment holds out hope to paralyzed people, but at how great a risk?
As yet another biofuels company prepares for a stock offering, some wonder if the company is worthy of going public at all.
Ubiquitous handsets introduce mobile payments to those who lack bank accounts.
Brazil's investment in transgenic animals shows how opposition to such technologies in the United States is opening opportunities elsewhere.
How unauthorized video producers are "brand-jacking" companies and forcing them to rethink the way they market.
California-based Amyris has used breakthroughs in synthetic biology to reinvent biofuels. To turn its technology into an industrial process, it has headed to the land of sugar: Brazil.
In the Bolivian Andes lies a vast salt flat that may shape the future of transportation.